Summary

Artificial Retina Implant Market Research Report Information by Product (Enzymes, Pharma Products, Bulk Chemicals, and Others), by Application (Bioengineering, Genomics, Vaccine Development, Drug Discovery, Fisheries, Aquaculture, Biofuels, Water Treatment Services, and Others), and by End User (Hospitals, Pharmaceutical Companies, Biotechnology Companies, and Others) and by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032

Market Overview
In 2025, the Artificial Retina Implant Market was estimated at USD 1.51 billion. The Artificial Retina Implant industry is expected to increase from USD 1.92 billion in 2026 to USD 7.04 billion by 2032, with a compound annual growth rate (CAGR) of 21.22% for the forecast period (2026-2032).
The global market is being driven by rising occurrences of age-related macular degeneration (AMD) and retinitis pigmentosa, as well as a growing number of companies focused on artificial retina implants.
Bionic Vision Technologies, a well-known name in the field of artificial retina technology, announced a significant collaboration with Cirtec Medical, a renowned medical technology firm headquartered in the United States, in September 2021. The collaborative effort will facilitate the design process, allowing for joint production of the next generation of bionic eyes. With access to Cirtec Medical's knowledge base and resources, Bionic Vision Technologies hopes to strengthen its breakthrough bionic eye technology and provide a better vision solution for those suffering from visual impairments.
Market Segment insights
The Artificial Retina Market is divided into three product types: epiretinal implants, subretinal implants, and suprachoroidal implants.
The Artificial Retina Market is divided into two applications: age-related macular degeneration (AMD) and retinitis pigmentosa.
Regional insights
The study divides the market into four regions: North America, Europe, Asia-Pacific, and the rest of the world. The North American artificial retina implant market had the greatest market share of more than 50.12% in 2025, owing to rising prevalence of age-related macular degeneration (AMD) and the presence of FDA-approved implant products. For example, Argus II is a product available in the United States that has been FDA-approved.
The European artificial retina implant market is expected to increase significantly during the projected year, 2025-2026, as a result of frequent strategic alliances between industry competitors to meet customer demands. For example, in July 2022, Pixium Vision (France) reported the successful implantation of the first patient in the Netherlands in the Prima System European pivotal trial PRIMAvera. Pixium Vision has since developed more clinical locations and implanted patients in both Germany and the United Kingdom.

The Asia-Pacific artificial retina implant market is expected to develop at the quickest rate during the projected period, owing to the region's growing geriatric population, which would significantly contribute to market growth. According to the Asia-Pacific Report on Population Ageing 2022, there were roughly 670 million persons aged 60 and over in Asia-Pacific in 2022. In Asia-Pacific, the population is expected to quadruple to almost 1.3 billion people by 2050.

Major Players
Bionic Vision Technologies (US), PIXIUM VISION (France), Optobionics (US), Labtician Ophthalmics, Inc (Canada), Vivani Medical Inc. (US), iBIONICS (Canada), LambdaVision, Inc. (US), AXORUS (France), Sensor-Tech Lab (Russia), and Nanovision (US) are among the key players in the Artificial Retina Implant Market.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE AND ASSUMPTIONS
2.5 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA FLOW
3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
3.5.1 PRIMARY RESEARCH DATA FLOW:
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
3.7.1 DATA FORECASTING TECHNIQUE
3.8 DATA MODELING
3.8.1 MICROECONOMIC FACTOR ANALYSIS:
3.8.2 DATA MODELING:
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 INCREASING INCIDENCES OF AGE-RELATED MACULAR DEGENERATION (AMD) AND RETINITIS PIGMENTOSA
4.2.2 GROWING NUMBER OF STARTUPS ASSOCIATED WITH ARTIFICIAL RETINA IMPLANT
4.3 RESTRAINTS
4.3.1 HIGH COST ASSOCIATED WITH ARTIFICIAL RETINA IMPLANT PROCEDURES
4.4 OPPORTUNITY
4.4.1 INCREASING FUNDING & INVESTMENT FOR ARTIFICIAL RETINA IMPLANT
5 MARKET FACTOR ANALYSIS
5.1 PORTER'S FIVE FORCES MODEL
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 BARGAINING POWER OF SUPPLIERS
5.1.3 THREAT OF SUBSTITUTES
5.1.4 BARGAINING POWER OF BUYERS
5.1.5 INTENSITY OF RIVALRY
5.2 KEY PLAYERS DEVELOPING BRAIN IMPLANTS TO TREAT VISION LOSS
6 GLOBAL ARTIFICIAL RETINA IMPLANT MARKET, BY PRODUCT TYPE
6.1 OVERVIEW
6.2. EPIRETINAL IMPLANTS
6.3. SUBRETINAL IMPLANTS
6.4. SUPRACHOROIDAL IMPLANTS
7 GLOBAL ARTIFICIAL RETINA IMPLANT MARKET, BY APPLICATION
7.1 OVERVIEW
7.2. AGE-RELATED MACULAR DEGENERATION (AMD)
7.3. RETINITIS PIGMENTOSA
8 GLOBAL ARTIFICIAL RETINA IMPLANT MARKET, BY REGION
8.1 OVERVIEW
9 COMPETITIVE LANDSCAPE
9.1 INTRODUCTION
9.2 COMPETITOR DASHBOARD
9.3 PUBLIC PLAYERS STOCK SUMMARY
9.4 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
9.5 KEY DEVELOPMENTS & GROWTH STRATEGIES
9.5.1 PARTNERSHIP
9.5.2 EXPANSION
9.5.3 MERGER
10 COMPANY PROFILES
10.1 VIVANI MEDICAL INC.
10.1.1 COMPANY OVERVIEW
10.1.2 FINANCIAL OVERVIEW
10.1.3 PRODUCTS OFFERED
10.1.4 KEY DEVELOPMENTS
10.1.5 SWOT ANALYSIS
10.1.6 KEY STRATEGIES
10.2 IBIONICS
10.2.1 COMPANY OVERVIEW
10.2.2 FINANCIAL OVERVIEW
10.2.3 PRODUCTS OFFERED
10.2.4 KEY DEVELOPMENTS
10.2.5 SWOT ANALYSIS
10.2.6 KEY STRATEGY
10.3 NANOVISION BIOSCIENCES
10.3.1 COMPANY OVERVIEW
10.3.2 FINANCIAL OVERVIEW
10.3.3 PRODUCTS OFFERED
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGY
10.4 SENSOR-TECH LAB
10.4.1 COMPANY OVERVIEW
10.4.2 FINANCIAL OVERVIEW
10.4.3 PRODUCTS OFFERED
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGY
10.5 LABTICIAN OPHTHALMICS, INC
10.5.1 COMPANY OVERVIEW
10.5.2 FINANCIAL OVERVIEW
10.5.3 PRODUCTS OFFERED
10.5.4 KEY DEVELOPMENTS
10.5.5 SWOT ANALYSIS
10.5.6 KEY STRATEGIES
10.6 OPTOBIONICS
10.6.1 COMPANY OVERVIEW
10.6.2 FINANCIAL OVERVIEW
10.6.3 PRODUCTS OFFERED
10.6.4 KEY DEVELOPMENTS
10.6.5 KEY STRATEGIES
10.7 LAMBDAVISION, INC.
10.7.1 COMPANY OVERVIEW
10.7.2 FINANCIAL OVERVIEW
10.7.3 PRODUCTS OFFERED
10.7.4 KEY DEVELOPMENTS
10.7.5 SWOT ANALYSIS
10.7.6 KEY STRATEGIES
10.8 BIONIC VISION TECHNOLOGIES
10.8.1 COMPANY OVERVIEW
10.8.2 FINANCIAL OVERVIEW
10.8.3 PRODUCTS/SERVICES OFFERED
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIES
10.9 PIXIUM VISION
10.9.1 COMPANY OVERVIEW
10.9.2 FINANCIAL OVERVIEW
10.9.3 PRODUCTS OFFERED
10.9.4 KEY DEVELOPMENTS
10.9.5 SWOT ANALYSIS
10.9.6 KEY STRATEGIES
10.10 AXORUS
10.10.1 COMPANY OVERVIEW
10.10.2 FINANCIAL OVERVIEW
10.10.3 PRODUCTS OFFERED
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIES
10.11 DATA CITATIONS